Upstream Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
Upstream Bio, Inc. (UPB), a Delaware corporation listed on the Nasdaq Global Select Market, filed this Current Report on Form 8-K on March 26, 2026. The filing reports the entry into a material definitive agreement to facilitate an "at-the-market" (ATM) equity offering.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial metric disclosed is the potential capital raise:
- Maximum Offering Size: Up to $150,000,000 in aggregate sales price.
- Agent Commission: Up to 3.0% of gross proceeds from sales.
Material Changes
The primary material change is the execution of a Sales Agreement with Leerink Partners LLC, acting as sales agent. This agreement authorizes the Company to offer and sell shares of its common stock from time to time through the Agent. The offering is conducted pursuant to a shelf registration statement (Form S-3ASR) filed on November 5, 2025, and a prospectus supplement filed on March 26, 2026.
Outlook, Risks, and Management Commentary
Management Commentary: The Company is not obligated to sell any shares, and the Agent is not required to sell any specific number or dollar amount. Sales will be made based on the Company's instructions regarding price, time, or size limits.
Flexibility and Termination: Either the Company or the Agent may suspend or terminate the offering or the Sales Agreement at any time upon notice to the other party.
Risks and Contingencies: The filing notes that sales are subject to applicable state and federal laws and Nasdaq rules. No sale will occur in any state where the offer or sale would be unlawful prior to registration or qualification.
Key Facts for Investor Verification
- Verify the current share price and market capitalization to assess the potential dilution impact of a full $150 million offering.
- Review the Company's cash position and burn rate to determine the immediate necessity of this capital raise.
- Confirm the status of the underlying shelf registration statement (File No. 333-291267) and any subsequent amendments.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.